Abstract:Chronic infection of hepatitis B virus (HBV) is still one of the public health concerns affecting human health. Although the prophylactic HBV vaccines was introduced over three decades ago, the total number of chronic hepatitis B (CHB) infection still accounts for 3.5% (257 million) of the world's population, with approximately 800000 annual deaths related to the viral infection. Currently, drugs including PEG-IFN and NAs are widely used in the treatment of HBV infection with certain degree of success. It is still difficult to achieve a high proportion of "clinical cure" with existing treatment methods. The presence of covalently closed circular DNA (cccDNA) in the infected hepatocytes is the underlying mechanism for the long-term HBV persistence and is also essential for off-therapy viral relapse. The current treatments have no or limited effects on the suppression of intrahepatic cccDNA. The availability for a reliable cccDNA quantification assay would facilitate the developmentof anti-viral drugs targeting cccDNA-targeting. In this review, we summarized the advantages and disadvantages of the existing methods for cccDNA quantitation. Specifically, the extraction method of Hirt DNA combined with Exonuclease V can effectively remove other forms of HBV DNA, and suitable for cccDNA extraction, but it needs to be further optimized. Southern blot is considered as the "gold-standard" method for cccDNA detection, but it is less sensitive and requires cumbersome procedures, making it an unlikely method for high-throughput screening used for drug development or for clinical applications. The PCR-based methods are more convenient and sensitive for cccDNA detection. However, the reliability of PCR-based method requires further optimization and validation. Different PCR-based methods were developed for quantitation of HBV cccDNA. They include selective qPCR, droplet-digital PCR, rolling circle amplification PCR, in situ PCR, invader assay, magnetic capture hybridization qPCR, etc. These PCR-based methods are widely used in clinical and laboratory research for quantitation of cccDNA. Efforts need to be made to minimize the interference from other forms of DNAs in the assays. More recently, hepatitis B core related antigen (HBcrAg)was found to be a novel marker of HBV, and its level in serum is highly correlated with intracellular cccDNA level. This biomarker, the HBcrAg level, can be used to indicate the suppression of cccDNA during different clinical antiviral therapies. The correlation needs further analysis with additional data sets. In summary, we present a review on the quantitation assays for HBV cccDNA. Such assays are important for drug developments and clinical applications for improved management of HBV infection related diseases. Performance and characteristics of various methods were compared with the areas of improvements for different assays.

Application of in Situ Hybridization in the Detection of Hepatitis B Virus Nucleic Acids and Cccdna

A Chromogenic In Situ Hybridization (CISH) Assay for Detection of HBV RNA, DNA, and cccDNA in Liver Tissue

In Situ Analysis of Intrahepatic Virological Events in Chronic Hepatitis B Virus Infection.

Clinical Relevance of the in Situ Assay for HBV DNA: a Cross-Sectional Study in Patients with Chronic Hepatitis B

A Fluorescent In Situ Hybridization (FISH) Assay for Detection of HBV RNA, DNA, and cccDNA in Cell Culture.

Establishment of a Fluorescent in Situ Hybridization Assay for Imaging Hepatitis B Virus Nucleic Acids in Cell Culture Models.

The Clinical Study on the Detecting Simultaneity HBV DNA in the Serum and Liver Tissuse of Patients with DNA Microarry Technique

Hepatitis Gene Chip in Detecting HBV DNA, HCV RNA in Serum and Liver Tissue Samples of Hepatitis Patients.

Detection of HBV-cccDNA in Hepatic Cells by in Situ PCR

Detection of HBV Covalently Closed Circular DNA

The current and future applications of in situ hybridization technologies in anatomical pathology

Clinical significance and detection of human granulose cells in HBV carriers in situ hybridization methods

Comparison of Different In Situ Hybridization Techniques for the Detection of Various RNA and DNA Viruses

A quantitative method for hepatitis B virus covalently closed circular DNA enables distinguishing direct acting antivirals from cytotoxic agents

In situ analysis of hepatitis B virus (HBV) antigen and DNA in HBV-induced hepatocellular carcinoma

Detection of HBV DNA in Kidneys of HBV-associated Glomerulonephritis Using in Situ Hybridization and in Situ PCR Technique

A sensitive and quantitative immunochromatographic assay for HBsAg based on novel red silica nanoparticles

Quantatitative Assays For Covalently Closed Circular Dna Of Hepatitis B Virus

Recent Advances in High-sensitivity In Situ Hybridization and Costs and Benefits to Consider When Employing These Methods

In Situ Hybridization of Breast Cancer Markers.

[Establishment and Application of Nested Real-Time Quantitative Polymerase Chain Reaction Assay for Detection of Hepatitis B Virus Covalently Closed Circular DNA].